Flibanserin Evening Dosing for Post-Menopausal Sexual Desire Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for post-menopausal Sexual Desire Disorders are inadequate in addressing the specific needs of hypoactive sexual desire in post-menopausal women, particularly in terms of efficacy and tolerability, as existing therapies do not effectively differentiate between lifelong and acquired disorders or consider the various etiologic origins.
Innovation Solution
The use of flibanserin, in the form of its hydrochloride, free base, or pharmacologically acceptable salts and solvates, administered daily in the evening, specifically targeting hypoactive sexual desire disorders in post-menopausal women, regardless of the disorder's type or etiologic origin, through various pharmaceutical formulations such as tablets, capsules, or suppositories, to improve tolerability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If flibanserin is administered once daily in the evening, then tolerability is improved by minimizing sedation side effects, but treatment duration requirement increases
Solution Approach 1:
The patent implements periodic administration of flibanserin once daily in the evening, creating a rhythmic treatment pattern that allows the body to metabolize the drug during daytime hours, thereby reducing cumulative sedation effects while maintaining therapeutic efficacy through consistent daily exposure
Solution Approach 2:
The patent optimizes the dosing time parameter by administering flibanserin specifically in the evening, which changes the pharmacokinetic profile and reduces daytime sedation. This temporal parameter adjustment allows the same drug to have different side effect profiles based on administration timing
2Adaptability or versatility
If flibanserin is used to treat both lifelong and acquired Sexual Desire Disorders regardless of etiologic origin, then adaptability of the treatment is improved, but treatment complexity increases
Solution Approach 1:
The patent establishes flibanserin as a universal treatment for hypoactive sexual desire disorders, making it applicable across multiple subtypes (lifelong/acquired, generalized/situational, different etiologic origins) without requiring different medications, thereby simplifying the overall treatment landscape despite the diversity of conditions
3Ease of operation
If various pharmaceutical formulations of flibanserin are provided, then ease of operation is improved for patient convenience, but manufacturing complexity increases
Solution Approach 1:
The patent segments flibanserin treatment into multiple pharmaceutical formulations (tablets, capsules, suppositories, oral solutions) that can be manufactured separately using different processes optimized for each dosage form, allowing parallel development and manufacturing rather than attempting to modify a single formulation
Data Source
AI summary
The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of post-menopausal Sexual Desire Disorders.